What we do:

The Claremont Amany Institute of Cancer Genomics is a hematologic cancer–focused research and biobanking institute dedicated to ethically collecting, integrating, and analyzing biospecimens, genomic data, and longitudinal clinical information from African populations. We translate these data into actionable insights that advance precision oncology, therapeutic development, and equitable cancer care globally.

Learn More
 

Integrated Genomic & Clinical Data

Each biospecimen is linked to:

  • Genomic data (e.g., sequencing, molecular profiling)

  • Longitudinal clinical phenotypes

  • Treatment, response, and outcome data

  • Real-world electronic medical record (EMR) data

This integrated approach creates a uniquely powerful resource for translational research.

Longitudinal Follow-Up

Patients are followed prospectively, enabling:

  • Disease evolution and resistance studies

  • Outcome-based biomarker discovery

  • Real-world effectiveness analyses

Research & Commercial Access

Under a robust governance framework, CAICG provides access to:

  • Academic researchers

  • Biotechnology and pharmaceutical partners

  • Diagnostics and precision-medicine developers

Access models include curated sample access, data licensing, and collaborative research partnerships.